448 related articles for article (PubMed ID: 9151799)
1. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.
Sheng H; Shao J; Kirkland SC; Isakson P; Coffey RJ; Morrow J; Beauchamp RD; DuBois RN
J Clin Invest; 1997 May; 99(9):2254-9. PubMed ID: 9151799
[TBL] [Abstract][Full Text] [Related]
2. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis.
Erickson BA; Longo WE; Panesar N; Mazuski JE; Kaminski DL
J Surg Res; 1999 Jan; 81(1):101-7. PubMed ID: 9889067
[TBL] [Abstract][Full Text] [Related]
3. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells.
Sheng H; Shao J; Morrow JD; Beauchamp RD; DuBois RN
Cancer Res; 1998 Jan; 58(2):362-6. PubMed ID: 9443418
[TBL] [Abstract][Full Text] [Related]
4. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
[TBL] [Abstract][Full Text] [Related]
5. Meloxicam inhibits the growth of colorectal cancer cells.
Goldman AP; Williams CS; Sheng H; Lamps LW; Williams VP; Pairet M; Morrow JD; DuBois RN
Carcinogenesis; 1998 Dec; 19(12):2195-9. PubMed ID: 9886578
[TBL] [Abstract][Full Text] [Related]
6. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.
Grösch S; Tegeder I; Niederberger E; Bräutigam L; Geisslinger G
FASEB J; 2001 Dec; 15(14):2742-4. PubMed ID: 11606477
[TBL] [Abstract][Full Text] [Related]
7. A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts.
Williams CS; Sheng H; Brockman JA; Armandla R; Shao J; Washington MK; Elkahloun AG; DuBois RN
Neoplasia; 2001; 3(5):428-36. PubMed ID: 11687954
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase-2 expression is abundant in alveolar type II cells in lung cancer-sensitive mouse strains and in premalignant lesions.
Wardlaw SA; March TH; Belinsky SA
Carcinogenesis; 2000 Jul; 21(7):1371-7. PubMed ID: 10874016
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
Spinella F; Rosanò L; Di Castro V; Nicotra MR; Natali PG; Bagnato A
Clin Cancer Res; 2004 Jul; 10(14):4670-9. PubMed ID: 15269139
[TBL] [Abstract][Full Text] [Related]
10. Antioxidants reduce cyclooxygenase-2 expression, prostaglandin production, and proliferation in colorectal cancer cells.
Chinery R; Beauchamp RD; Shyr Y; Kirkland SC; Coffey RJ; Morrow JD
Cancer Res; 1998 Jun; 58(11):2323-7. PubMed ID: 9622066
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells.
Coffey RJ; Hawkey CJ; Damstrup L; Graves-Deal R; Daniel VC; Dempsey PJ; Chinery R; Kirkland SC; DuBois RN; Jetton TL; Morrow JD
Proc Natl Acad Sci U S A; 1997 Jan; 94(2):657-62. PubMed ID: 9012840
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522.
Tomozawa S; Nagawa H; Tsuno N; Hatano K; Osada T; Kitayama J; Sunami E; Nita ME; Ishihara S; Yano H; Tsuruo T; Shibata Y; Muto T
Br J Cancer; 1999 Dec; 81(8):1274-9. PubMed ID: 10604722
[TBL] [Abstract][Full Text] [Related]
13. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F
Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433
[TBL] [Abstract][Full Text] [Related]
14. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2.
Pyo H; Choy H; Amorino GP; Kim JS; Cao Q; Hercules SK; DuBois RN
Clin Cancer Res; 2001 Oct; 7(10):2998-3005. PubMed ID: 11595687
[TBL] [Abstract][Full Text] [Related]
15. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
[TBL] [Abstract][Full Text] [Related]
16. Gene modulation by Cox-1 and Cox-2 specific inhibitors in human colorectal carcinoma cancer cells.
Bottone FG; Martinez JM; Alston-Mills B; Eling TE
Carcinogenesis; 2004 Mar; 25(3):349-57. PubMed ID: 14633654
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor.
Petersen C; Petersen S; Milas L; Lang FF; Tofilon PJ
Clin Cancer Res; 2000 Jun; 6(6):2513-20. PubMed ID: 10873107
[TBL] [Abstract][Full Text] [Related]
18. Role of constitutive cyclooxygenase-2 in prostaglandin-dependent secretion in mouse colon in vitro.
MacNaughton WK; Cushing K
J Pharmacol Exp Ther; 2000 May; 293(2):539-44. PubMed ID: 10773026
[TBL] [Abstract][Full Text] [Related]
19. Dual acting anti-inflammatory drugs: a reappraisal.
Bertolini A; Ottani A; Sandrini M
Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
[TBL] [Abstract][Full Text] [Related]
20. COX-2, NSAIDs and human neoplasia. Part I: Colorectal neoplasms.
Nasir A; Fernandez PM; Chughtai OR; Kaiser HE
In Vivo; 2002; 16(6):501-9. PubMed ID: 12494894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
